Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 28;8(1):180.
doi: 10.1038/s41746-025-01569-3.

Leveraging electronic medical records to evaluate a computerized decision support system for staphylococcus bacteremia

Affiliations

Leveraging electronic medical records to evaluate a computerized decision support system for staphylococcus bacteremia

Julia Palm et al. NPJ Digit Med. .

Abstract

Infectious disease specialists (IDS) improve outcomes of patients with Staphylococcus bacteremia, but immediate IDS access is not always guaranteed. We investigated whether a care-integrated computerized decision support system (CDSS) can safely enhance the standard of care (SOC) for these patients. We conducted a multicenter, noninferiority, interventional stepped-wedge cluster randomized controlled trial relying on the data integration centers at five university hospitals. By this means, electronic medical records can be used for part of the trial documentation. We analyzed 5056 patients from 134 wards (Staphylococcus aureus (SAB): n = 812, coagulase-negative staphylococci (CoNS): n = 4244) and found that the CDSS was noninferior to the SOC for hospital mortality in all patients. Noninferiority regarding the 90-day mortality/relapse in SAB patients was not observed and there was no evidence for differences in vancomycin usage among CoNS patients. Despite low reported usage, physicians rated the CDSS's usability favorably. Trial registration: drks.de; Identifier: DRKS00014320; Registration Date: 2019-05-06.

PubMed Disclaimer

Conflict of interest statement

Competing interests: O.W. has received research grants for clinical studies, speaker fees, honoraria and travel expenses from Amgen, Alexion, Astellas, Astra Zeneca, Basilea, Biotest, Bristol-Myers Squibb, Correvio, Chiesi, Gilead, GSK; Hexal, Janssen, Dr. F. Köhler Chemie, MSD, Novartis, Roche, Pfizer, Sanofi, Takeda, TEVA, Tillotts Pharma and UCB. OW is supported by an unrestricted grant from the Rudolf-Ackermann-Stiftung (Stiftung für Klinische Infektiologie). MPl has received speaker fees and honoraria from MSD, Pfizer, GSK, Gilad, Thermo Fisher, Infectopharm, Roche and BioNtech and has received a Pfizer grant for a study on CAP. SH has received speaker fees from Pfizer, MSD, Infectopharm, Philips, Advanz, Beckman Coulter, Shionogi, and Tillots. G.M. has received speaker fees and honoraria from März AG, BBraun Melsungen and 4TEEN4. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Recruitment CONSORT flowchart.
Due to the stepped-wedge design, each ward took part in the SOC phase at the beginning of the trial and switched to the CDSS phase at a randomized crossover point in time, thus contributing patients from both phases to the analysis. Numbers of patients are displayed for each type of bacteremia separately.
Fig. 2
Fig. 2. Differences in endpoint probability between the SOC and CDSS phases.
The gray boxes show the area of noninferiority (=5% of the SOC phase probability). Overlapping CIs indicate that noninferiority could not be established, while the CIs left of the gray box indicate noninferiority. Confidence intervals: 90% for noninferiority hypotheses and 95% for superiority hypotheses.
Fig. 3
Fig. 3. Usability rating of the HELP CDSS.
Physicians rated 10 statements on the CDSS’s usability, using a scale from “strongly agree” to “strongly disagree.” Each bar shows the percentage of physicians who agreed with each category for each statement.
Fig. 4
Fig. 4. Impact of the CDSS on clinical decisions and patient safety.
Physicians rated 10 statements on their clinical decisions and patient safety, using a scale from “strongly agree” to “strongly disagree.” Each bar shows the percentage of physicians who agreed with each category for each statement.
Fig. 5
Fig. 5. Schematic representation of the HELP CDSS.
Rough overview of the decision algorithm that was the basis for the HELP CDSS.
Fig. 6
Fig. 6. Data extraction process.
Starting with FHIR data available in each DIC, each step of the data extraction required iterative adaptions until the local analysis result was ready to be sent to the central analysis site.

References

    1. Diekema, D. J. et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis.32, S114–S132 (2001). - PubMed
    1. Schmitt, S. et al. Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. Clin. Infect. Dis.58, 22–28 (2014). - PubMed
    1. Vogel, M. et al. Infectious disease consultation for Staphylococcus aureus bacteremia—a systematic review and meta-analysis. J. Infect.72, 19–28 (2016). - PubMed
    1. Benfield, T. et al. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin. Microbiol. Infect.13, 257–263 (2007). - PubMed
    1. López-Cortés, L. E. et al. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin. Infect. Dis.57, 1225–1233 (2013). - PubMed

Grants and funding

LinkOut - more resources